
Colgate-Palmolive (CL) received a 68% rating from Validea's Patient Investor model, which is based on Warren Buffett's strategy, falling short of the 80% threshold typically indicating investment interest. While the large-cap personal and household products company demonstrated strengths in earnings predictability, debt service, and free cash flow, its performance on Return on Equity and Return on Total Capital were notable weaknesses, preventing a stronger endorsement from this value-oriented framework.
Colgate-Palmolive (CL) receives a mixed evaluation from Validea's Patient Investor model, which is structured on Warren Buffett's investment principles. The company scored 68%, falling below the 80% threshold that indicates a strategy's interest. The analysis reveals a dichotomy in the company's fundamentals: CL passes key tests for earnings predictability, debt service, free cash flow generation, use of retained earnings, and share repurchases, signaling operational stability and shareholder-friendly capital management. However, the company fails on two critical profitability metrics: Return on Equity (ROE) and Return on Total Capital (ROTC). These specific failures are significant detractors within the Buffett framework, suggesting that while the business is predictable and manages debt well, its ability to generate high returns on its capital base is currently subpar according to this model.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment